Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c

November 3, 2016 4:47 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $32.42 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment